Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
Other material
confidence 75%
filed 2026-06-09
Item 8.01
PSCo filed a $190 million natural gas rate case with the CPUC in December 2025, with intervenor testimony filed in June 2026 proposing significantly lower revenue increases ($85–$86 million excluding depreciation adjustments) and reduced ROE (8.5–9.2% vs. PSCo's 10.75% request). The filing discloses a material regulatory proceeding with a decision anticipated in Q4 2026 that will directly affect PSCo's revenue and profitability. While this is a regulatory rate case rather than a discrete event like M&A, covenant breach, or impairment, the magnitude and forward-looking impact on a major subsidiary's financial results make it material to investors assessing Xcel Energy's earnings trajectory.
View raw filing on EDGAR →
Earnings release
confidence 98%
filed 2026-06-09
Item 2.02
The Company issued a press release on June 9, 2026 announcing financial results for the quarter ended April 30, 2026, with the press release attached as Exhibit 99.1. This is a standard quarterly earnings disclosure under Item 2.02, which is material to investors as it provides the most recent financial performance data.
View raw filing on EDGAR →
Other material
confidence 75%
filed 2026-06-09
Item 8.01
Tyson Foods is recasting prior-period financial statements to reflect a material change in segment reporting methodology—specifically, the exclusion of corporate expenses and amortization from segment profit calculations and the identification of International as a new reportable segment. While this is not a restatement (the company explicitly states it "does not amend or restate" the consolidated financial statements), the recasting of segment data in response to an accounting change is material to investors' understanding of segment performance and resource allocation. This disclosure does not fit the specific restatement category (which typically involves non-reliance on previously issued statements due to errors or irregularities) but is a material accounting change requiring disclosure under SEC rules.
View raw filing on EDGAR →
Exec departure
confidence 95%
filed 2026-06-09
Item 5.02
Michael Newbanks, Vice President of Finance and Chief Accounting Officer, departed on June 5, 2026, after serving in that role since July 2017. The disclosure explicitly states he "left his position" and confirms no disagreement with the Company or Board. While a successor (Eric Sachs) is being transitioned into the role, the principal disclosed action is Newbanks' departure from a named executive officer position, making this an exec_departure event.
View raw filing on EDGAR →
Exec departure
confidence 95%
filed 2026-06-09
Item 5.02
Dennis Klaeser, a Board member and member of multiple committees (Executive, Audit, Compensation, Risk, and Capital), resigned effective immediately on June 5, 2026. The disclosure centers on his departure from the Board and Bank Board after 5 years of service. While the company states the resignation is not due to disagreement, the loss of a director with significant committee responsibilities is material to investors assessing board composition and governance.
View raw filing on EDGAR →
Exec Compensation
confidence 95%
filed 2026-06-09
Item 5.02
The Compensation Committee approved increases to Deborah Andrews' annual base salary (from $512,000 to $575,000) and target annual cash bonus (from 55% to 60% of base salary), effective June 8, 2026. This is a direct disclosure of compensatory arrangements for a named executive officer, fitting the exec_compensation category. The adjustments are material as they represent a meaningful increase in total compensation for a senior officer (Interim Co-CEO and CFO).
View raw filing on EDGAR →
Shareholder vote
confidence 98%
filed 2026-06-09
Item 5.07
This is a clear disclosure of shareholder voting results from FirstCash Holdings' Annual Meeting of Stockholders held on June 9, 2026, covering four proposals: election of directors, ratification of auditor (RSM LLP), advisory vote on named executive officer compensation, and approval of reincorporation to Texas. The filing explicitly states voting tallies for each proposal, which is the hallmark of Item 5.07 shareholder vote results disclosures.
View raw filing on EDGAR →
M&A activity
confidence 95%
filed 2026-06-09
Item 7.01
The filing discloses the completion of an acquisition of Stone Ridge Contracting, LLC by Sterling Infrastructure, Inc. The press release announcement of a closed acquisition constitutes material M&A activity under Item 1.01 or 2.01 of Form 8-K, even though it is being furnished under Item 7.01 (Regulation FD Disclosure). Acquisition completions are material events affecting the registrant's business and financial position.
View raw filing on EDGAR →
Shareholder vote
confidence 98%
filed 2026-06-09
Item 5.07
Ligand Pharmaceuticals held its Annual Meeting of stockholders on June 5, 2026, with shareholders voting on four proposals: election of eight board directors, ratification of Ernst & Young LLP as auditor, advisory vote on named executive officer compensation, and approval of an amended 2002 Stock Incentive Plan. All proposals passed with disclosed vote tallies.
View raw filing on EDGAR →
Dilutive issuance
confidence 94%
filed 2026-06-09
Item 1.01
Aspira Women's Health entered into a private placement securities purchase agreement on June 5, 2026, issuing 3,300,000 shares of common stock and warrants to purchase 4,455,000 additional shares to accredited and institutional investors for approximately $1.485 million in gross proceeds.
View raw filing on EDGAR →
Earnings release
confidence 98%
filed 2026-06-09
Item 2.02
The filing discloses financial results for the third fiscal quarter ended May 2, 2026, via a press release furnished as Exhibit 99.1. This is a standard quarterly earnings release under Item 2.02, which is material to investors as it provides the company's periodic financial performance and is central to investment decision-making.
View raw filing on EDGAR →
Earnings release
confidence 95%
filed 2026-06-09
Item 2.02
AITX issued a press release confirming audited fiscal year 2026 results and filing of Form 10-K, disclosing revenue growth and gross margin expansion.
View raw filing on EDGAR →
Other material
confidence 65%
filed 2026-06-09
Item 7.01
DraftKings disclosed significant month-over-month growth metrics for its Predictions offering (24% consumer volume increase to $1.3B annualized, 34% total volume increase to $3.1B annualized). While these are preliminary operating metrics rather than audited financial results, the substantial growth rates and the company's choice to disclose them via 8-K suggest material business developments. However, the disclosure lacks the formal structure of an earnings release and the company explicitly disclaims materiality, making classification ambiguous between earnings-related disclosure and other material event.
View raw filing on EDGAR →
Exec departure
confidence 95%
filed 2026-06-09
Item 5.02
Jared Oasheim, the Chief Financial Officer, gave notice of his intention to resign on June 7, 2026, to pursue other professional opportunities. While the disclosure includes compensatory arrangements (transition payments, consulting fees, stock option extensions), the principal disclosed action is the CFO's departure. The company is initiating a search for a successor, confirming this is a material executive departure that would affect investor assessment of management continuity and financial oversight.
View raw filing on EDGAR →
Dilutive issuance
confidence 35%
filed 2026-06-09
Item 8.01
The filing announces a $1.2 billion private offering of senior notes due 2031 and 2034, offered to qualified institutional buyers under Rule 144A and Regulation S. While this is a material debt issuance, the event is primarily a debt offering rather than an equity issuance. The dilutive_issuance category is typically reserved for unregistered equity sales (PIPEs, convertibles, ATM offerings). This disclosure is more accurately characterized as debt financing activity, which does not fit neatly into the provided taxonomy and may be better classified as other_material.
View raw filing on EDGAR →
Exec appointment
confidence 85%
filed 2026-06-09
Item 5.02
Dr. Michael Philip Kimel was appointed as Chief Financial Officer effective June 9, 2026, with a base salary of $350,000 and a pending equity award. Steven Perez was simultaneously appointed as an independent director with $120,000 annual cash compensation. These appointments represent material changes to the registrant's executive and board leadership.
View raw filing on EDGAR →
Other material
confidence 65%
filed 2026-06-09
Item 8.01
Ameriprise Financial issued $750 million in aggregate principal amount of senior notes ($300M due 2031 at 4.800% and $450M due 2036 at 5.350%) on June 9, 2026. While this is a material debt issuance that would affect a reasonable investor's assessment of the company's capital structure and financial obligations, it does not fit cleanly into the more specific event categories. This is a registered public offering of debt securities disclosed under Item 8.01 (Other Events) rather than a covenant breach, dilutive equity issuance, or other enumerated event type.
View raw filing on EDGAR →
M&A activity
confidence 95%
filed 2026-06-09
Item 8.01
The filing discloses a material update on a pending merger: Esperion entered into a Merger Agreement with ArchiMed SAS affiliates on May 1, 2026, and on June 8, 2026, received clearance from the German antitrust authority (Bundeskartellamt). The disclosure explicitly states the Merger remains subject to HSR clearance and stockholder approval at a special meeting scheduled for July 8, 2026. This is a significant M&A milestone that would materially affect investor assessment of the company's future.
View raw filing on EDGAR →
M&A activity
confidence 95%
filed 2026-06-09
Item 1.01
The filing discloses entry into a material definitive agreement for the acquisition of a commercial real property (16,100 sq ft automotive service building in Kansas) for $5.8 million, with closing expected within 45 days. This is a classic Item 1.01 material acquisition event. The Company's plan to assign interests to a Delaware statutory trust and raise capital through a private placement of beneficial interests further confirms the materiality of this transaction to investors assessing the registrant's asset base and capital structure.
View raw filing on EDGAR →
Exec Compensation
confidence 95%
filed 2026-06-09
Item 5.02
The filing discloses an amended and restated employment agreement for Ms. Cindy Lee, the Chief Financial Officer, detailing her base salary ($500,000), discretionary bonus eligibility, a special long-term equity award of 20,000 RSUs vesting over three years, severance provisions including change-of-control protections (2.5x base salary plus bonus), and benefits continuation. This is a material compensatory arrangement for a named executive officer that would affect investor assessment of executive costs and retention incentives.
View raw filing on EDGAR →
Other material
confidence 72%
filed 2026-06-09
Item 7.01
Cartesian Therapeutics disclosed entry into a strategic licensing agreement with WestGene Biopharma for development of novel in vivo CAR-T therapies in autoimmune diseases. While this is a material partnership/licensing arrangement that could affect the company's pipeline and strategic direction, it does not fit cleanly into the M&A taxonomy (which focuses on acquisitions, dispositions, mergers, or changes of control). The licensing agreement is a material collaboration event that a reasonable investor would want to know about, but lacks the acquisition/merger/control-change characteristics of ma_activity.
View raw filing on EDGAR →
M&A activity
confidence 95%
filed 2026-06-09
Item 1.01
This disclosure concerns an amendment to a previously announced merger agreement between Lisata Therapeutics and Kuva Labs Inc., extending key deadlines (tender offer commencement from June 1 to June 10, 2026, and the Outside Date from July 1 to July 17, 2026) and modifying payment obligations and waivers. The amendment directly relates to the ongoing merger transaction and materially affects its timing and conditions, making it a material M&A activity event under Item 1.01.
View raw filing on EDGAR →
M&A activity
confidence 85%
filed 2026-06-09
Item 7.01
Allegiant Travel completed the acquisition of Sun Country Airlines Holdings, Inc., financed in part through approximately $224.7 million in aircraft financing transactions completed between April and May 2026. Pro forma financial information reflecting the combined entity's capital structure and financial position was disclosed.
View raw filing on EDGAR →
Dilutive issuance
confidence 75%
filed 2026-06-09
Item 8.01
Allegiant Travel commenced a $500 million private offering of senior secured notes due 2031 to qualified institutional buyers under Rule 144A and Regulation S, concurrent with a tender offer for $403 million of existing 2027 notes.
View raw filing on EDGAR →
M&A activity
confidence 97%
filed 2026-06-09
Item 1.01
Novanta Inc. entered into an Equity Purchase Agreement on June 8, 2026, to acquire all issued and outstanding interests of Runway Buyer for $1.2 billion in closing consideration plus a $250 million milestone payment, subject to HSR approval and other regulatory conditions. The transaction was announced via press release on June 9, 2026, with forward-looking statements addressing expected timing, completion, anticipated synergies, and integration risks.
View raw filing on EDGAR →
Earnings release
confidence 98%
filed 2026-06-09
Item 2.02
Lands' End disclosed financial results for the first quarter ended May 1, 2026, furnished as a press release exhibit.
View raw filing on EDGAR →
Other material
confidence 65%
filed 2026-06-09
Item 7.01
The company announced a conference call and investor presentation to discuss Q1 FY2026 financial results and strategy following the closing of a joint venture transaction with WHP Global.
View raw filing on EDGAR →
M&A activity
confidence 97%
filed 2026-06-09
Item 1.01
Nuvalent entered into an Agreement and Plan of Merger with GlaxoSmithKline LLC on June 9, 2026, whereby GSK will commence a tender offer at $124.00 per share, followed by a merger if conditions are satisfied. This is a material acquisition and change of control transaction.
View raw filing on EDGAR →
Other material
confidence 65%
filed 2026-06-09
Item 8.01
The filing discloses a press release reporting AUM as of May 31, 2026, filed under Item 8.01 (Other Events). While AUM is a key operational metric for asset management firms, this disclosure does not fit the standard earnings_release category (which typically reports quarterly or annual financial results with comprehensive income statement and balance sheet data). The filing appears to be a standalone AUM update rather than a full earnings release, making other_material the most appropriate classification, though the materiality depends on whether the AUM figures represent significant changes that would affect investor assessment of the company's business performance.
View raw filing on EDGAR →
Earnings release
confidence 92%
filed 2026-06-09
Item 8.01
This Item 8.01 disclosure presents Mercury General's consolidated financial highlights for Q1 2026 and full-year 2025, including net premiums earned, net income, and operating income figures. The filing includes detailed financial tables comparing Q1 2026 to Q1 2025 and full-year 2025 to 2024, along with reconciliations to GAAP measures. This constitutes a material earnings disclosure that would affect investor assessment of the company's financial performance and operational trends.
View raw filing on EDGAR →
Cybersecurity Incident
confidence 95%
filed 2026-06-09
Item 8.01
The filing discloses a material cybersecurity incident at Evertec, a third-party core processing provider, affecting customer data of BPPR (Popular's Puerto Rico subsidiary). The compromised data includes personal information, debit card numbers, and other customer information. Although the Corporation states it does not currently believe the incident is reasonably likely to have material impact, the disclosure itself—involving customer data compromise, regulatory notification, and enhanced fraud monitoring—constitutes a material cybersecurity incident requiring 8-K disclosure under Item 1.05 rules (effective 2023).
View raw filing on EDGAR →
Other material
confidence 65%
filed 2026-06-09
Item 2.03
This Item 2.03 disclosure reports the creation of direct financial obligations through the issuance of consolidated obligations (bonds and discount notes) by the Federal Home Loan Bank of Pittsburgh. While the filing explicitly states "consolidated obligations issuance is material to the FHLBank," the disclosure is primarily informational and regulatory in nature—describing the mechanics of consolidated obligation issuance, the joint and several liability structure, and the exclusions from Schedule A. The filing does not disclose a specific new debt covenant, acceleration clause, or cross-default trigger that would constitute a "covenant_breach" event. The materiality lies in the ongoing debt issuance program rather than a discrete triggering event, making "other_material" the most appropriate classification.
View raw filing on EDGAR →
Other material
confidence 65%
filed 2026-06-09
Item 1.01
Sherwin-Williams entered into Amendment No. 11 to its credit facility, extending $200 million in credit commitments from June 2026 to June 2031. This material financing arrangement affects the company's liquidity and capital structure flexibility.
View raw filing on EDGAR →
Other material
confidence 65%
filed 2026-06-09
Item 7.01
The filing discloses an updated 2026 outlook following the acquisition of Thermon Group Holdings, Inc., issued via press release on June 9, 2026. While the acquisition itself would typically be classified as ma_activity, this Item 7.01 disclosure focuses on the forward guidance update rather than the acquisition event itself. The guidance update is material to investors assessing future performance, but the disclosure is furnished (not filed) under Regulation FD, and the core acquisition event likely appears elsewhere in the 8-K. This is best classified as other_material since it is a material forward-looking statement tied to a completed acquisition, but does not fit neatly into earnings_release (no historical results) or the ma_activity category (the acquisition is referenced as context, not as the primary disclosed event).
View raw filing on EDGAR →
Shareholder vote
confidence 95%
filed 2026-06-09
Item 5.07
This is a clear disclosure of shareholder vote results from the June 4, 2026 annual meeting of stockholders. The filing reports the final voting tallies for two proposals: (1) election of Wendell E. Pritchett as a Class III director with 18,436,266 votes for and zero against, and (2) ratification of Deloitte & Touche LLP as independent auditor with identical voting results. This is a routine but material Item 5.07 disclosure required by SEC rules for annual meeting outcomes.
View raw filing on EDGAR →
M&A activity
confidence 75%
filed 2026-06-09
Item 1.01
PennantPark Private Income Fund entered into a second amendment to its senior secured revolving credit facility on June 5, 2026, increasing borrowing capacity from $120.0 million to $200.0 million. While this is a credit facility amendment rather than a traditional M&A transaction, it represents a material change to the registrant's financing structure and debt capacity, which would affect a reasonable investor's assessment of the company's liquidity and financial flexibility. The 67% increase in available borrowing capacity is a material financial event disclosed under Item 1.01.
View raw filing on EDGAR →
Shareholder vote
confidence 98%
filed 2026-06-09
Item 5.07
Verrica Pharmaceuticals held an Annual Meeting of Stockholders with four proposals: election of directors, advisory approval of named executive officer compensation, ratification of KPMG LLP as auditor, and approval of the Amended and Restated 2018 Equity Incentive Plan. Vote results for all four proposals are disclosed with detailed tallies.
View raw filing on EDGAR →
Shareholder vote
confidence 98%
filed 2026-06-09
Item 5.07
Shareholders voted on June 3, 2026 at the Annual Meeting and approved four proposals: election of directors Donna Corley and Tela Mathias as Class II directors, ratification of Deloitte as independent auditor, advisory approval of named executive officer compensation, and approval of a reverse stock split amendment to the Certificate of Incorporation.
View raw filing on EDGAR →
Shareholder vote
confidence 98%
filed 2026-06-09
Item 5.07
This is a classic Item 5.07 disclosure reporting the final results of the Company's 2026 Annual Meeting of Stockholders held on June 3, 2026. The filing presents voting tallies for two proposals: election of three Class I directors (Robert A. Lenz, Rebecca Luse, and Ran Nussbaum) and ratification of BDO USA, P.C. as independent auditor. All proposals passed with substantial majorities. Shareholder vote results are material to investors as they confirm board composition and auditor appointment.
View raw filing on EDGAR →
M&A activity
confidence 95%
filed 2026-06-09
Item 1.01
Inflection Point Acquisition Corp. III entered into Amendment No. 2 to its Business Combination Agreement with Air Water Ventures Holdings Limited, materially reducing aggregate base consideration from $300M to $200M, restructuring earnout triggering events, and reducing maximum earnout shares from 30M to 20M.
View raw filing on EDGAR →
Dilutive issuance
confidence 85%
filed 2026-06-09
The filing discloses an unregistered sale of 2,701,420 shares of common stock by certain stockholders acquired in connection with Ondas Inc.'s acquisition of Omnisys Ltd. The shares are being registered for resale via a prospectus supplement to an S-3ASR registration statement. This represents a dilutive equity issuance material to investors assessing ownership and capital structure, particularly given the acquisition context and the substantial share count involved.
View raw filing on EDGAR →
M&A activity
confidence 95%
filed 2026-06-09
Item 7.01
The filing discloses entry into a Business Combination Agreement dated May 25, 2026, between Axiom Intelligence Acquisition Corp 1 (SPAC) and Terra Quantum AG, representing a material acquisition/merger transaction. The disclosure details the parties, agreement structure, and contemplated shareholder vote, which are hallmarks of M&A activity under Item 1.01 or 2.01. This is a transformative event for the SPAC and would materially affect investor assessment of the registrant.
View raw filing on EDGAR →
Other material
confidence 75%
filed 2026-06-09
Item 8.01
The disclosure announces a mandatory separation of the Company's units into separately traded Class A Ordinary Shares (ticker "APUR") and Rights (ticker "APURR") effective June 10, 2026. While this is a structural capital markets event affecting how the Company's securities trade, it does not fit neatly into the more specific event categories (not an M&A activity, not a dilutive issuance, not a delisting). The event is material to investors as it changes the trading mechanics and liquidity profile of the Company's securities, warranting disclosure under Item 8.01 as an "Other Event."
View raw filing on EDGAR →
M&A activity
confidence 92%
filed 2026-06-09
Item 8.01
This Item 8.01 disclosure centers on a Forward Purchase Agreement entered into on June 1, 2026, in connection with Live Oak Acquisition Corp. V's proposed initial business combination with Teamshares Inc. The filing discloses the trust account redemption price ($10.55 per share as of June 8, 2026) and references the underlying Merger Agreement dated November 14, 2025 (as amended). While the Item 8.01 framing emphasizes the trust disclosure requirement, the substantive event is the material acquisition/business combination activity—the forward purchase transaction is a financing mechanism directly tied to the proposed merger. This is a core M&A event material to investors assessing the registrant's strategic direction and capital structure.
View raw filing on EDGAR →
Delisting risk
confidence 98%
filed 2026-06-09
Item 3.01
Jasper Therapeutics received written notice from Nasdaq on June 3, 2026, that its voting common stock bid price closed below the $1.00 minimum requirement for 30 consecutive business days under Nasdaq Listing Rule 5550(a)(2). The company has been granted an initial 180-day compliance period (until November 30, 2026) to regain compliance, with potential for a second 180-day period if certain conditions are met. This is a classic delisting risk disclosure under Item 3.01, materially affecting investor assessment of the company's continued public trading status.
View raw filing on EDGAR →
Other material
confidence 65%
filed 2026-06-09
Item 7.01
The disclosure announces two developments: (1) mobilization of field crews and commencement of the 2026 summer exploration program at the Upper Kobuk Mineral Projects (a material asset for a mineral exploration company), and (2) appointment of a new President at Ambler Metals LLC, the joint venture advancing the project. While the appointment of a new President at the joint venture could suggest exec_appointment, the filing does not clarify whether this person is a named executive of Trilogy itself or merely of the joint venture entity. The primary focus appears to be the operational milestone (field operations underway), which is material to investors in an exploration-stage company but does not fit neatly into the standard taxonomy categories. Classified as other_material given the ambiguity around the appointment's scope and the operational significance of the exploration program announcement.
View raw filing on EDGAR →
Earnings release
confidence 98%
filed 2026-06-09
Item 2.02
Designer Brands Inc. issued a press release on June 9, 2026 announcing consolidated financial results for the quarter ended May 2, 2026, filed under Item 2.02 (Results of Operations and Financial Condition). The disclosure explicitly references a press release attached as Exhibit 99.1 containing quarterly financial results, which is the standard form of earnings release disclosure.
View raw filing on EDGAR →
Shareholder vote
confidence 98%
filed 2026-06-09
Item 5.07
This is a classic Item 5.07 disclosure reporting the results of Palantir's June 3, 2026 annual meeting of stockholders. The filing details voting outcomes for six proposals: election of seven directors (all elected), ratification of Ernst & Young as independent auditor, advisory approval of named executive officer compensation, and three stockholder proposals (all rejected). The detailed vote tallies for each nominee and proposal are the core content of the disclosure.
View raw filing on EDGAR →
Other material
confidence 65%
filed 2026-06-09
Item 2.03
This Item 2.03 disclosure describes the issuance of consolidated obligations (bonds and discount notes) by the Federal Home Loan Bank of Des Moines. While the filing creates a direct financial obligation under Item 2.03, the prose does not disclose a specific debt covenant breach, cross-default, or triggering event that accelerates financial obligations—the hallmarks of covenant_breach. Instead, it describes the routine issuance mechanism and regulatory framework for consolidated obligations. The materiality statement ("although consolidated obligations issuance is material to the Bank") indicates the event is material, but the specific event type does not fit cleanly into the more specific categories; it is best classified as other_material given the regulatory and structural nature of the disclosure.
View raw filing on EDGAR →
Other material
confidence 65%
filed 2026-06-09
Item 2.03
This 8-K Item 2.03 discloses the issuance of a $250 million consolidated obligation bond (Variable Single Index Floater, maturing 09/04/2026, trade date 06/05/2026). While Item 2.03 is technically designed for covenant breaches and direct financial obligations, the FHLBank's disclosure here focuses on the creation of a debt obligation through consolidated bond issuance rather than a covenant breach or triggering event. This is material to investors as it represents a significant new debt obligation, but it does not fit cleanly into the more specific event categories (covenant_breach applies to triggering events that accelerate obligations, not routine debt issuance). The filing itself notes that "consolidated obligations issuance is material to the FHLBank," supporting materiality.
View raw filing on EDGAR →